Top pick for
All rounder
How to buy GlaxoSmithKline shares | 1616.4p
Here's how you can invest in the British pharmaceutical giant.
Fact checked
The global stock market has taken a big hit recently due to the ongoing coronavirus pandemic. While the GSK share price has also dropped, investors may see it GlaxoSmithKline shares as a safer long-term bet, especially given its history with developing vaccines. GlaxoSmithKline plc (LON:GSK) is a British pharmaceutical company based in Brentford. It is part of the FTSE 100 and helped developed the world’s first malaria vaccine in 2014.
How to buy shares in GlaxoSmithKline
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: GSK in this case.
- Research GlaxoSmithKline shares. The platform should provide the latest information available.
- Buy your GlaxoSmithKline shares. It's that simple.
What's in this guide?
- Can I buy shares in GlaxoSmithKline?
- Has coronavirus impacted GlaxoSmithKline shares?
- GlaxoSmithKline shares summary
- Compare share dealing platforms
- Is GlaxoSmithKline stock a buy or sell?
- GlaxoSmithKline performance over time
- Is GlaxoSmithKline suitable for ethical investing?
- Are GlaxoSmithKline shares over-valued?
- GlaxoSmithKline's financials
- How volatile are GlaxoSmithKline shares?
- Does GlaxoSmithKline pay a dividend?
- Have GlaxoSmithKline shares ever split?
- Other common questions
How has Coronavirus impacted GlaxoSmithKline's share price?
Since the stock market crash in March caused by coronavirus, GlaxoSmithKline's share price has had significant negative movement.
Its last market close was 1617p, which is 2.48% down on its pre-crash value of 1658.2p and 21.74% up on the lowest point reached during the March crash when the shares fell as low as 1328.1874p.
If you had bought £1,000 worth of GlaxoSmithKline shares at the start of February 2020, those shares would have been worth £763.32 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £897.92.
GlaxoSmithKline share price
Use our graph to track the performance of GSK stocks over time.GlaxoSmithKline shares at a glance
Information last updated 2020-07-08.
| Open | 1609.2p |
|---|---|
| High | 1628p |
| Low | 1605.8p |
| Close | 1616.4p |
| Previous close | 1617p |
| Change | -0.6p |
| Change % | -0.037% |
| Volume | 592,383 |
Information last updated 2020-08-02.
| 52-week range | 1328.1874p - 1857p |
|---|---|
| 50-day moving average | 1523.7253p |
| 200-day moving average | 1608.7522p |
| Wall St. target price | 1644.5p |
| PE ratio | 11.5064 |
| Dividend yield | 0.76p (4.97%) |
| Earnings per share (TTM) | 132.7p |
Invest in shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- Automatically copy the leading traders on the platform
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Is it a good time to buy GlaxoSmithKline stock?
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
GlaxoSmithKline price performance over time
Historical closes compared with the last close of 1616.4p
| 1 week (2020-08-03) | N/A |
|---|---|
| 1 month (2020-07-10) | 2.63% |
| 3 months (2020-05-14) | -1.55% |
| 6 months (2020-02-10) | N/A |
| 1 year (2019-08-10) | N/A |
|---|---|
| 2 years (2018-08-10) | N/A |
| 3 years (2017-08-10) | N/A |
| 5 years (2015-08-10) | N/A |
Is GlaxoSmithKline under- or over-valued?
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's P/E ratio
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, GlaxoSmithKline shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, GlaxoSmithKline's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.
- Pfizer (PFE.US): 15.13
- Gilead Sciences (GILD.US): 18.91
- Johnson-and-Johnson (JNJ.US): 25.93
- Abbott Laboratories (ABT.US): 59.16
- IDEXX Laboratories (IDXX.US): 74.67
- AstraZeneca (AZN.LSE): 69.27
GlaxoSmithKline's PEG ratio
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.7688. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider GlaxoSmithKline's PEG ratio in relation to those of similar companies.
- Pfizer (PFE.US): 2.76
- Gilead Sciences (GILD.US): 0.47
- Johnson-and-Johnson (JNJ.US): 3.61
- Abbott Laboratories (ABT.US): 4.52
- IDEXX Laboratories (IDXX.US): 9.09
- AstraZeneca (AZN.LSE): 1.62
GlaxoSmithKline's EBITDA
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £9.1 billion.
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
To put GlaxoSmithKline's EBITDA into context you can compare it against that of similar companies.
- Pfizer (PFE.US): USD$20.1 billion
- Gilead Sciences (GILD.US): USD$5.6 billion
- Johnson-and-Johnson (JNJ.US): USD$27.2 billion
- Abbott Laboratories (ABT.US): USD$7.6 billion
- IDEXX Laboratories (IDXX.US): USD$698.2 million
- AstraZeneca (AZN.LSE): £6.9 billion
GlaxoSmithKline financials
| Revenue TTM | £35 billion |
|---|---|
| Operating margin TTM | 25.01% |
| Gross profit TTM | £23 billion |
| Return on assets TTM | 7.38% |
| Return on equity TTM | 63.64% |
| Profit margin | 19.08% |
| Book value | 2.731p |
| Market capitalisation | £76.8 billion |
TTM: trailing 12 months
GlaxoSmithKline's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like GlaxoSmithKline.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
GlaxoSmithKline's total ESG risk score
Total ESG risk: 28.93
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and GlaxoSmithKline's overall score of 28.93 (as at 07/01/2020) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like GlaxoSmithKline is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare GlaxoSmithKline's total ESG risk score against those of similar companies.
- Pfizer (PFE.US): 33.15
- Gilead Sciences (GILD.US): 21.95
- Johnson-and-Johnson (JNJ.US): 35.78
- Abbott Laboratories (ABT.US): 33.33
- IDEXX Laboratories (IDXX.US): 30.77
- AstraZeneca (AZN.LSE): 28.59
GlaxoSmithKline's environmental score
Environmental score: 3.49/100
GlaxoSmithKline's environmental score of 3.49 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that GlaxoSmithKline is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
GlaxoSmithKline's social score
Social score: 15.58/100
GlaxoSmithKline's social score of 15.58 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that GlaxoSmithKline is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
GlaxoSmithKline's governance score
Governance score: 11.37/100
GlaxoSmithKline's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that GlaxoSmithKline is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
GlaxoSmithKline's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. GlaxoSmithKline scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that GlaxoSmithKline hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
- Pfizer (PFE.US): 3
- Gilead Sciences (GILD.US): 2
- Johnson-and-Johnson (JNJ.US): 4
- Abbott Laboratories (ABT.US): 3
- AstraZeneca (AZN.LSE): 3
Environmental, social, and governance (ESG) summary
GlaxoSmithKline plc was last rated for ESG on: 2020-07-01.
| Total ESG score | 28.93 |
|---|---|
| Total ESG percentile | 40.84 |
| Environmental score | 3.49 |
| Environmental score percentile | 6 |
| Social score | 15.58 |
| Social score percentile | 6 |
| Governance score | 11.37 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
GlaxoSmithKline share dividends
Dividend payout ratio: 60.2% of net profits
Recently GlaxoSmithKline has paid out, on average, around 60.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.97% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 4.97% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about 0.76p per share.
GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 13 August 2020 (the "ex-dividend date").
GlaxoSmithKline's dividend payout ratio is perhaps best considered in relation to those of similar companies.
- Pfizer (PFE.US): 58.50%
- Gilead Sciences (GILD.US): 65.90%
- Johnson-and-Johnson (JNJ.US): 67.84%
- Abbott Laboratories (ABT.US): 79.07%
- IDEXX Laboratories (IDXX.US): 0.00% (does not pay dividend)
- AstraZeneca (AZN.LSE): 167.85%
Have GlaxoSmithKline's shares ever split?
GlaxoSmithKline's shares were split on a 2:1 basis on 28 October 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
GlaxoSmithKline share price volatility
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as 1328.1874p up to 1857p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while GlaxoSmithKline's is 0.4238. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
To put GlaxoSmithKline's beta into context you can compare it against those of similar companies.
- Pfizer (PFE.US): 0.7335
- Gilead Sciences (GILD.US): 0.656
- Johnson-and-Johnson (JNJ.US): 0.694
- Abbott Laboratories (ABT.US): 0.9775
- IDEXX Laboratories (IDXX.US): 0.8034
- AstraZeneca (AZN.LSE): 0.2762
GlaxoSmithKline overview
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Frequently asked questions
Ask an Expert